ReviewPharmacoepidemiology and drug safety2022
Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting.
Review in Pharmacoepidemiology and drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antipsychotic Drug Interactions and Short-Term Mortality Risk in People With Dementia: A National Cohort Study.Clinical pharmacology and therapeutics · 2026Article
- Employing General-Purpose and Biomedical Large Language Models with Advanced Prompt Engineering for Pharmacoepidemiologic Study Design.Pharmaceutical research · 2026Article
- Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population-Based Cohort Study.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Potential bias in observational PCSK9 inhibitor study.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Real-world evidence: state-of-the-art and future perspectives.Journal of comparative effectiveness research · 2025Review
- Transparency in the secondary use of health data: assessing the status quo of guidance and best practices.Royal Society open science · 2025Article
- Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Real-World Evidence BRIDGE: A Tool to Connect Protocol With Code Programming.Pharmacoepidemiology and drug safety · 2024Article
- Characterizing timeliness of recommended vaccinations among privately-insured children in the United States, 2009-2019.Vaccine · 2024Article
- Article
- Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study.Drug safety · 2023Article
- Pharmacoepidemiology: An Overview.Journal of clinical medicine · 2023Review
- Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting.Pharmacoepidemiology and drug safety · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transparency is increasingly promoted to instill trust in nonrandomized studies using real-world data. Graphics and data visualizations support transparency by aiding communication and understanding, and can inform study design and analysis decisions. However, other than graphical representation of a study design and flow diagrams (e.g., a Consolidated Standards of Reporting Trials [CONSORT] like diagram), specific standards on how to maximize validity and transparency with visualization are needed. This paper provides guidance on how to use visualizations throughout the life cycle of a pharmacoepidemiology study-from initial study design to final report-to facilitate rationalized and transparent decision-making about study design and implementation, and clear communication of study findings. Our intent is to help researchers align their practices with current consensus statements on transparency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.